MAQUET positioniert sich als fhrender

Document Sample
MAQUET positioniert sich als fhrender Powered By Docstoc
					P RE S S RE LE AS E
JULY 2010



THE CARDIOHELP SYSTEM
FOR EFFECTIVE CARDIOPULMONARY SUPPORT


Cardiovascular diseases are the most common cause of
death worldwide. The occurrence of life-threatening
cardiovascular and pulmonary diseases, such as ALCOS
(Acute Low Cardiac Output Syndrome), ARDS (Acute
Respiratory Distress Syndrome), septic shock, pulmonary
embolism or multiple organ failure is high.


German-based medical technology manufacturer
MAQUET Cardiopulmonary AG has developed the world’s
most compact and lightweight heart-lung support system.
The portable CARDIOHELP System is suitable for all
patients requiring extracorporeal cardiopulmonary support
and/or a reduction in blood CO 2 levels.


Medical professionals have long been looking for more
effective and more efficient therapy options for patients
needing intensive care. The CARDIOHELP System
provides extracorporeal circulatory support that facilitates
new approaches to therapies that are more effective,
gentler on the patient, and more efficient than existing
therapies.




MAQUET Cardiopulmonary AG
Hechinger Straße 38
72145 Hirrlingen, Germany
Press Contact:
Marcus C. Felstead
Phone: +49 (0) 7478 921-205
Fax:   +49 (0) 7478 921-400
E-mail: Marcus.Felstead@maquet-cp.com                          Page 1
P RE S S RE LE AS E
JULY 2010




The portable CARDIOHELP System is characterized by a
short preparation time and its user-friendly operation and
management. Using disposables, such as a gas
exchanger and appropriate cannulae, the system provides
vital extracorporeal gas exchange and circulatory support
for up to 30 days of continuous use. In this way, the
system effectively buys the time needed for the disease to
be treated and for the patient’s body to be able to resume
its own oxygen supply activities.


Thanks to the low volume of the extracorporeal circuit, the
size of the foreign surface area with which the blood
comes into contact is reduced, thereby minimizing blood
trauma. Furthermore, less volume is required to prime the
extracorporeal circuit. Extracorporeal support with the
CARDIOHELP System is therefore much gentler on
patients than other existing support systems.


Since the patient can remain attached to the system for
the duration of the support period, and the disposables
don’t need replacing due to wear, the CARDIOHELP
System is also extremely cost-effective.




MAQUET Cardiopulmonary AG
Hechinger Straße 38
72145 Hirrlingen, Germany
Press Contact:
Marcus C. Felstead
Phone: +49 (0) 7478 921-205
Fax:   +49 (0) 7478 921-400
E-mail: Marcus.Felstead@maquet-cp.com                         Page 2
P RE S S RE LE AS E
JULY 2010



Using veno-venous or veno-arterial cannulation,
extracorporeal circulation can be set up to support cardiac
and/or pulmonary function. Support can be extended to
complete substitution of heart and lung functions. Indeed
optimum treatment of these patient groups pre-supposes
logical, well adapted management using conventional
ventilation techniques, for example with SERVO-i from
MAQUET and perfusion using the CARDIOHELP System.
Even during intra- or inter-hospital transport, the portable
system provides adequate patient oxygen supply and
CO 2 reduction.


CO 2 reduction enables protective ventilation


Acute Respiratory Distress Syndrome (ARDS) refers to a
massive pulmonary shock in response to harmful factors.
This respiratory failure is often triggered by sepsis,
polytrauma, pneumonia, or aspiration. Despite all efforts in
intensive care to modify ventilation patterns, the mortality
rate for ARDS is still over 50%. Every day, 1.400 persons
die across the globe as a result of sepsis and/or septic
shock.




MAQUET Cardiopulmonary AG
Hechinger Straße 38
72145 Hirrlingen, Germany
Press Contact:
Marcus C. Felstead
Phone: +49 (0) 7478 921-205
Fax:   +49 (0) 7478 921-400
E-mail: Marcus.Felstead@maquet-cp.com                          Page 3
P RE S S RE LE AS E
JULY 2010



The veno-venous use of the CARDIOHELP System
ensures an effective oxygen supply and/or the reduction of
blood CO 2 levels in intensive care patients suffering from
ARDS, sepsis or other indications associated with acute
respiratory failure. In this way the CARDIOHELP System
facilitates protective ventilation strategies even in severe
cases of acute respiratory failure. Moreover CARDIOHELP
prevents circulatory shock or damage to internal organs.
This reduces the follow-up costs which would occur with
irreversible organ damage. The use of this therapy option
therefore saves valuable time, which can then be used to
treat the actual cause of an organ failure.


CARDIOHELP can be managed and monitored by nursing
staff using a single rotary knob and a touchscreen. A
specially trained person is always on call via an
emergency call system. MAQUET’s modular training
program instructs medical professionals in the use of the
CARDIOHELP System for different patient extracorporeal
support applications.


MAQUET has developed the Heart Lung Support (HLS)
Module Advanced for long-term use. In addition to an
artificial lung it also features an integrated VAD pump




MAQUET Cardiopulmonary AG
Hechinger Straße 38
72145 Hirrlingen, Germany
Press Contact:
Marcus C. Felstead
Phone: +49 (0) 7478 921-205
Fax:   +49 (0) 7478 921-400
E-mail: Marcus.Felstead@maquet-cp.com                          Page 4
P RE S S RE LE AS E
JULY 2010



(ventricular assist pump). The HLS Module Advanced also
contains sensors for venous, internal and arterial blood
pressure, and arterial temperature. This is the world’s first
disposable to offer a high-tech sensor for the continuous
measurement of the important parameters - venous
saturation (S v O 2 ), hematocrit (HCT) and hemoglobin (Hb)
plus venous temperature (T v ). Until now, this was only
possible using an external blood analyzer. The HLS
Module Advanced is approved for up to 30 days of
continuous use.



About MAQUET Cardiovascular

       MAQUET Cardiovascular was formed in 2003 and is a leader

in providing innovative products for cardiac surgery, vascular

intervention and cardiac support to hospitals and clinics and cardiac

surgeons, interventional cardiologists, perfusionists and other

healthcare professionals who care for patients with cardiovascula r

disease. MAQUET Cardiovascular is focused on providing clinicians

with future-oriented technology that fits into their daily practice and

improves the therapeutic management of patients. MAQUET

Cardiovascular continues to invest in the development of inn ovative

technologies and solutions that advance clinical practice, improve

patient outcomes and enhance the quality of life.




MAQUET Cardiopulmonary AG
Hechinger Straße 38
72145 Hirrlingen, Germany
Press Contact:
Marcus C. Felstead
Phone: +49 (0) 7478 921-205
Fax:   +49 (0) 7478 921-400
E-mail: Marcus.Felstead@maquet-cp.com                                     Page 5
P RE S S RE LE AS E
JULY 2010



       MAQUET Cardiovascular provides healthcare professionals

with products in four business units: Cardiopulmonary (perfusion

products), Cardiac Surgery (clampless beating heart and endoscopic

vessel harvesting), Vascular Interventions (grafts for vascular

surgery), and Cardiac Assist (intra-aortic balloon counterpulsation

therapy).



About The MAQUET Group

       The MAQUET Group is the global m arket leader for Medical

Systems, focusing on the Operating Room (OR), Cath eter Laboratory

(Cath Lab), Intensive Care Unit (ICU) and Patient Transport. The

integrated products of MAQUET are specially designed to deliver

optimal clinical treatment and thera peutic applications within acute

care hospitals. MAQUET provides innovative medical solutions from

three Divisions:
       Cardiovascular with products for cardiac assist (intra -aortic

balloon counterpulsation therapy), coronary artery bypass surgery,

complex aortic surgery reconstruction, peripheral interventions and

extracorporeal circulation.

   Critical Care for intensive care ventilators and anesthesia

   machines




MAQUET Cardiopulmonary AG
Hechinger Straße 38
72145 Hirrlingen, Germany
Press Contact:
Marcus C. Felstead
Phone: +49 (0) 7478 921-205
Fax:   +49 (0) 7478 921-400
E-mail: Marcus.Felstead@maquet-cp.com                                   Page 6
P RE S S RE LE AS E
JULY 2010



   Surgical Workplaces for OR tables, lights and ceiling service

   units, flexible room design for OR, Cath Lab and ICU as well as

   digital OR integration.



MAQUET is a subsidiary of the publicly-listed Swedish GETINGE

GROUP, a company with around EUR 2,190 billion in revenues

(2009 fiscal year) and 12,100 employees worldwide. In 2009

MAQUET itself generated revenues of around EUR 1,080 billion. The

company now has more than 5,000 employees in 36 international

sales and service organizations, as well as a network of more than

250 sales representatives. Twelve manufacturing sites are located in

6 countries.



www.maquet.com

www.getingegroup.com



MAQUET – The Gold Standard.




MAQUET Cardiopulmonary AG
Hechinger Straße 38
72145 Hirrlingen, Germany
Press Contact:
Marcus C. Felstead
Phone: +49 (0) 7478 921-205
Fax:   +49 (0) 7478 921-400
E-mail: Marcus.Felstead@maquet-cp.com                                  Page 7

				
DOCUMENT INFO
Shared By:
Categories:
Stats:
views:3
posted:4/11/2011
language:English
pages:7